for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alnylam Pharmaceuticals, Inc.

ALNY.OQ

Latest Trade

131.84USD

Change

-2.46(-1.83%)

Volume

168,871

Today's Range

130.79

 - 

134.75

52 Week Range

83.06

 - 

167.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
134.30
Open
134.75
Volume
168,871
3M AVG Volume
9.86
Today's High
134.75
Today's Low
130.79
52 Week High
167.24
52 Week Low
83.06
Shares Out (MIL)
115.97
Market Cap (MIL)
15,289.46
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Alnylam Pharmaceuticals Inc Earnings Release

Latest Developments

More

Alnylam Presents Positive Results From Illuminate-B Phase 3 Study In Pediatric Patients With Primary Hyperoxaluria Type 1 At The American Society Of Nephrology Kidney Week

Alnylam Reports Positive Results From Phase 3 Study Of Lumasiran For The Treatment Of Primary Hyperoxaluria

Alnylam Pharmaceuticals Reports Second Quarter 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections.

Industry

Biotechnology & Drugs

Contact Info

675 W Kendall St

CAMBRIDGE, MA

02142-1168

United States

+1.617.5518200

https://www.alnylam.com/

Executive Leadership

Michael W. Bonney

Independent Chairman of the Board

Yvonne L. Greenstreet

President, Chief Operating Officer

John M. Maraganore

Chief Executive Officer, Director

Jeffrey V. Poulton

Chief Financial Officer, Executive Vice President

Akshay K. Vaishnaw

President - Research and Development

Key Stats

2.04 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.2K

2020(E)

0.5K
EPS (USD)

2017

-5.420

2018

-7.570

2019

-8.110

2020(E)

-6.491
Price To Earnings (TTM)
--
Price To Sales (TTM)
44.29
Price To Book (MRQ)
10.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.47
Return on Equity (TTM)
-27.79

Latest News

Latest News

BRIEF-Alnylam Pharmaceuticals And Taiba Group Partner To Commercialize RNAi Therapeutics In The Gulf States

* ALNYLAM PHARMACEUTICALS AND TAIBA GROUP PARTNER TO COMMERCIALIZE RNAI THERAPEUTICS IN THE GULF STATES

BRIEF-Alnylam Reports New 12-Month Interim Data From The Envision Phase 3 Study Of Givosiran In Acute Hepatic Porphyria

* ALNYLAM REPORTS NEW 12-MONTH INTERIM DATA FROM THE ENVISION PHASE 3 STUDY OF GIVOSIRAN IN ACUTE HEPATIC PORPHYRIA

BRIEF-Alnylam Announces Publication Of Phase 3 Study Results For Givosiran In The New England Journal Of Medicine

* ALNYLAM ANNOUNCES PUBLICATION OF ENVISION PHASE 3 STUDY RESULTS FOR GIVOSIRAN IN THE NEW ENGLAND JOURNAL OF MEDICINE

BRIEF-Alnylam Presents Positive Phase 3 Results From ILLUMINATE-A Study Of Lumasiran

* ALNYLAM PRESENTS POSITIVE PHASE 3 RESULTS FROM ILLUMINATE-A STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1

BRIEF-Alnylam Announces U.S. FDA Has Granted Priority Review Of Lumasiran New Drug Application For Treatment Of Primary Hyperoxaluria Type 1

* ALNYLAM ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION HAS GRANTED PRIORITY REVIEW OF THE LUMASIRAN NEW DRUG APPLICATION FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1

BRIEF-Alnylam Pharmaceuticals Qtrly Loss Per Share Of $1.62

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

BRIEF-Alnylam Pharmaceuticals Reports Q1 2020 Financial Results

* ALNYLAM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

BRIEF-Vir and Alnylam Identify RNAi Therapeutic Development Candidate for the Treatment of COVID-19

* VIR AND ALNYLAM IDENTIFY RNAI THERAPEUTIC DEVELOPMENT CANDIDATE, VIR-2703 (ALN-COV), TARGETING SARS-COV-2 FOR THE TREATMENT OF COVID-19

Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

BRIEF-Alnylam Receives Fast Track Designation For Vutrisiran For Treatment Of Polyneuropathy Of Hattr Amyloidosis

* ALNYLAM RECEIVES FAST TRACK DESIGNATION FOR VUTRISIRAN FOR TREATMENT OF POLYNEUROPATHY OF HATTR AMYLOIDOSIS

Alnylam's gene-silencing efforts get $2 billion Blackstone backing

Blackstone Group Inc said on Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds.

Blackstone invests $2 bln in Alnylam Pharma

Blackstone Group Inc said on Monday it invested $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost to develop its experimental therapies.

BRIEF-Blackstone And Alnylam Enter Into $2 Billion Strategic Financing Collaboration

* BLACKSTONE AND ALNYLAM ENTER INTO $2 BILLION STRATEGIC FINANCING COLLABORATION TO ACCELERATE THE ADVANCEMENT OF RNAI THERAPEUTICS

BRIEF-Blackstone Invests $2 Billion In Alnylam Pharmaceuticals- WSJ

* BLACKSTONE INVESTS $2 BILLION IN ALNYLAM PHARMACEUTICALS- WSJ Source text: https://on.wsj.com/34vtAUW Further company coverage:

BRIEF-Alnylam Completes Rolling Submission Of New Drug Application To The U.S. FDA For Lumasiran For The Treatment Of Primary Hyperoxaluria Type 1

* ALNYLAM COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION AND SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR LUMASIRAN FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 Source text for Eikon:...

BRIEF-Vir And Alnylam Expand Collaboration To Advance Investigational RNAi Therapeutics Targeting Host Factors For The Treatment Of Covid-19

* VIR AND ALNYLAM EXPAND COLLABORATION TO ADVANCE INVESTIGATIONAL RNAI THERAPEUTICS TARGETING HOST FACTORS FOR THE TREATMENT OF COVID-19

BRIEF-Alnylam Pharma Signs Turkey Distribution Agreement

* ALNYLAM PHARMACEUTICALS AND GEN SIGN DISTRIBUTION AGREEMENT IN TURKEY FOR ONPATTRO® (PATISIRAN), THE FIRST-IN-CLASS ‘GENE-SILENCING’ RNAI THERAPEUTIC Source text for Eikon: Further company coverage:

Alnylam beats investor lawsuit over rare disease treatment

A federal judge has dismissed a lawsuit accusing Alnylam Pharmaceuticals Inc of misleading investors about the effectiveness and safety of a therapeutic injection it developed called Onpattro used to treat a rare hereditary disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up